Tirzepatide’s cardiovascular effects in clinical practice - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Tirzepatide’s cardiovascular effects in clinical practice

Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

  • By

  • Kathryn Wighton

  • August 28, 2026

  • 4 min

Share

  • 1

    Tirzepatide is associated with a lower 1-year risk of major adverse cardiovascular events compared to sitagliptin in patients with type 2 diabetes.

  • 2

    The study analyzed data from 52,971 patients aged 40 and older who initiated tirzepatide or sitagliptin between May 2022 and May 2025.

  • 3

    At 1 year, the weighted risk of major adverse cardiovascular events was approximately 3% for tirzepatide and 4% for sitagliptin.

  • 4

    Tirzepatide was linked to fewer infection-related hospital admissions and lower infection-related mortality compared to sitagliptin.

  • 5

    The study's limitations include a relatively short follow-up period and potential residual confounding affecting mortality findings.

Original Source(s)

Tirzepatide’s cardiovascular effects in clinical practice

  • by Kathryn Wighton

  • August 28, 2026

Related Content

Could Pregnancy Complications Predict CVD Risk?

Investigators found that adding pregnancy-related and female-specific factors modestly improved postpartum cardiovascular risk prediction compared with traditional risk factors alone.

Valve-like tissues may mimic inflammatory disease

Stem cell–derived tissues showed enhanced maturation and developed calcification-associated changes consistent with diseased human valve samples.

Micromegaly: a distinct clinical entity? Insights from a monocentric cohort study